Takeda Pharms Usa Drug Patent Portfolio
Takeda Pharms Usa owns 38 orange book drugs protected by 280 US patents with Carbatrol having the least patent protection, holding only 1 patent. And Vyvanse with maximum patent protection, holding 44 patents. Given below is the list of Takeda Pharms Usa's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11260064 | Stable corticosteroid compositions | 10 Jan, 2039 | Active |
| US11564934 | Stable corticosteroid compositions | 10 Jan, 2039 | Active |
| US10385078 | Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-YL) piperidin-1-YL]phenyl}pyrimidine-2,4-diamine | 10 Nov, 2035 | Active |
| US10519142 | Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide | 07 Sep, 2035 | Active |
| US11046674 | Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide | 07 Sep, 2035 | Active |
| US10227342 | Heteroaryl compounds for kinase inhibition | 13 May, 2035 | Active |
| US9796712 | Heteroaryl compounds for kinase inhibition | 13 May, 2035 | Active |
| US9611283 | Methods for inhibiting cell proliferation in ALK-driven cancers | 10 Apr, 2034 | Active |
| US11192895 | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt | 12 Dec, 2033 | Active |
| US11192897 | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt | 12 Dec, 2033 | Active |
| US11384086 | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1- yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt | 12 Dec, 2033 | Active |
| US9493470 | Crystalline forms of 3-(imidazo[1,2-B] pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt | 12 Dec, 2033 | Active |
| US9278096 | Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity | 21 Sep, 2032 | Active |
| US9278096 | Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity | 21 Mar, 2032 | Active |
| US9233103 | Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy | 05 Mar, 2032 | Active |
| US11684632 | Maribavir isomers, compositions, methods of making and methods of using | 04 Jan, 2032 | Active |
| US8722684 | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment | 30 Dec, 2031 | Active |
| US8372872 | Methods for concomitant treatment of theophylline and febuxostat | 08 Sep, 2031 | Active |
| US9107912 | Methods for concomitant treatment of theophylline and febuxostat | 08 Sep, 2031 | Active |
| US8722684 | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment | 30 Jun, 2031 | Active |
| US9012462 | Phosphorous derivatives as kinase inhibitors | 28 Apr, 2031 | Active |
| US8980327 | Capsule and powder formulations containing lanthanum compounds | 01 Dec, 2030 | Active |
| US9023397 | Capsule and powder formulations containing lanthanum compounds | 01 Dec, 2030 | Active |
| US8173158 | Methods of treating gastrointestinal disorders independent of the intake of food | 17 Sep, 2030 | Active |
| US8173158 | Methods of treating gastrointestinal disorders independent of the intake of food | 17 Mar, 2030 | Active |
| US7442830 | Proteasome inhibitors | 20 Nov, 2029 | Active |
| US8846100 | Controlled dose drug delivery system | 24 Aug, 2029 | Active |
| US8324192 | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract | 03 Aug, 2029 | Active |
| US9050368 | Corticosteroid compositions | 01 Aug, 2029 | Active |
| US8697125 | Tablet preparation without causing a tableting trouble | 16 Jun, 2029 | Active |
| US8859504 | Boronate ester compounds and pharmaceutical compositions thereof | 16 Jun, 2029 | Active |
| US9175017 | Boronate ester compounds and pharmaceutical compositions thereof | 16 Jun, 2029 | Active |
| US8637079 | Solid preparation comprising alogliptin and pioglitazone | 04 Jun, 2029 | Active |
| US8900638 | Solid preparation comprising alogliptin and metformin hydrochloride | 24 May, 2029 | Active |
| US9273077 | Phosphorus derivatives as kinase inhibitors | 21 May, 2029 | Active |
| US9241910 | Orally-disintegrating solid preparation | 10 Mar, 2029 | Active |
| US7820681 | Methods for concomitant administration of colchicine and a second active agent | 17 Feb, 2029 | Active |
| US7906519 | Methods for concomitant administration of colchicine and a second active agent | 17 Feb, 2029 | Active |
| US7915269 | Methods for concomitant administration of colchicine and a second active agent | 17 Feb, 2029 | Active |
| US8440721 | Methods for concomitant administration of colchicine and a second active agent | 17 Feb, 2029 | Active |
| US8440722 | Methods for concomitant administration of colchicine and a second active agent | 17 Feb, 2029 | Active |
| US7601758 | Methods for concomitant administration of colchicine and macrolide antibiotics in the treatment of gout flares | 10 Feb, 2029 | Active |
| US9320714 | Tablet | 03 Feb, 2029 | Active |
| US7619004 | Methods for concomitant administration of colchicine and macrolide antibiotics | 03 Dec, 2028 | Active |
| US7935731 | Methods for concomitant administration of colchicine and macrolide antibiotics | 03 Dec, 2028 | Active |
| US10293052 | Compositions for the treatment of gastrointestinal inflammation | 22 Nov, 2028 | Active |
| US11357859 | Compositions for the treatment of gastrointestinal inflammation | 12 Nov, 2028 | Active |
| US7964647 | Colchicine compositions and methods | 06 Oct, 2028 | Active |
| US7964648 | Methods for concomitant administration of colchicine and a second active agent | 06 Oct, 2028 | Active |
| US7981938 | Colchicine compositions and methods | 06 Oct, 2028 | Active |
| US8093296 | Methods for concomitant administration of colchicine and macrolide antibiotics | 06 Oct, 2028 | Active |
| US8093297 | Methods for concomitant administration of colchicine and a second active agent | 06 Oct, 2028 | Active |
| US8093298 | Methods for concomitant administration of colchicine and macrolide antibiotics | 06 Oct, 2028 | Active |
| US8097655 | Methods for concomitant administration of colchicine and macrolide antibiotics | 06 Oct, 2028 | Active |
| US8415395 | Colchicine compositions and methods | 06 Oct, 2028 | Active |
| US8415396 | Colchine compositions and methods | 06 Oct, 2028 | Active |
| US8871273 | Method for producing granules | 11 Jul, 2028 | Active |
| US7807689 | Dipeptidyl peptidase inhibitors | 27 Jun, 2028 | Active |
| US8071130 | Solid preparation | 08 Jun, 2028 | Active |
| US7829574 | Substituted quinazoline compounds and their use in treating angiogenesis-related diseases | 09 May, 2028 | Active |
| US8212033 | Use of substituted quinazoline compounds in treating angiogenesis-related diseases | 09 May, 2028 | Active |
| US8871273 | Method for producing granules | 11 Jan, 2028 | Active |
| US11458134 | 1-[2-(2,4-dimeihylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment | 15 Dec, 2027 | Active |
| US8969355 | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment | 15 Dec, 2027 | Active |
| US9125908 | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment | 15 Dec, 2027 | Active |
| US9125909 | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment | 15 Dec, 2027 | Active |
| US9125910 | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment | 15 Dec, 2027 | Active |
| US9227946 | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment | 15 Dec, 2027 | Active |
| US9861630 | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment | 15 Dec, 2027 | Active |
| US7687662 | Proteasome inhibitors | 06 Aug, 2027 | Active |
| US8003819 | Proteasome inhibitors | 06 Aug, 2027 | Active |
| US8530694 | Proteasome inhibitors | 06 Aug, 2027 | Active |
| US8871745 | Proteasome inhibitors | 06 Aug, 2027 | Active |
| US11458134 | 1-[2-(2,4-dimeihylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment | 15 Jun, 2027 | Active |
| US8969355 | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment | 15 Jun, 2027 | Active |
| US9125908 | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment | 15 Jun, 2027 | Active |
| US9125909 | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment | 15 Jun, 2027 | Active |
| US9125910 | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment | 15 Jun, 2027 | Active |
| US9227946 | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment | 15 Jun, 2027 | Active |
| US9861630 | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment | 15 Jun, 2027 | Active |
| US8105626 | Granules containing acid-unstable chemical in large amount | 27 Mar, 2027 | Active |
| US7790755 | Controlled release preparation | 02 Feb, 2027 | Active |
| US7700128 | Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester | 30 Jan, 2027 | Active |
| US8114874 | Substituted acetylenic imidazo[1,2-B]pyridazine compounds as kinase inhibitors | 24 Jan, 2027 | Active |
| US9101660 | Solid preparation | 22 Jan, 2027 | Active |
| US9029533 | Substituted acetylenic imidazo[1,2-A]pyridazines as kinase inhibitors | 22 Dec, 2026 | Active |
| US7144884 | Phenyl-piperazine derivatives as serotonin reuptake inhibitors | 17 Dec, 2026 | Active |
| US11197822 | Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract | 09 Nov, 2026 | Active |
| US11413296 | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract | 09 Nov, 2026 | Active |
| US8497258 | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract | 09 Nov, 2026 | Active |
| US8679545 | Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract | 09 Nov, 2026 | Active |
| US8975243 | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract | 09 Nov, 2026 | Active |
| US9119863 | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract | 09 Nov, 2026 | Active |
| US8105626 | Granules containing acid-unstable chemical in large amount | 27 Sep, 2026 | Active |
| US7790755 | Controlled release preparation | 02 Aug, 2026 | Active |
| US7785627 | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative | 31 Jul, 2026 | Active |
| US7959946 | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative | 31 Jul, 2026 | Active |
| US8461187 | Multiple PPI dosage form | 17 Jul, 2026 | Active |
| US7144884 | Phenyl-piperazine derivatives as serotonin reuptake inhibitors | 17 Jun, 2026 | Active |
| US7550433 | Erythropoietin receptor peptide formulations and uses | 02 Jun, 2026 | Active |
| US7919461 | Erythropoietin receptor peptide formulations and uses | 02 Jun, 2026 | Active |
| US9173857 | Controlled dose drug delivery system | 12 May, 2026 | Active |
| US7847061 | Treatment of short bowel syndrome patients with colon-in-continuity | 01 May, 2026 | Active |
| US9060992 | Treatment of short bowel syndrome patients with colon-in-continuity | 01 May, 2026 | Active |
| US9539310 | Treatment of short bowel syndrome patients with colon-in-continuity | 01 May, 2026 | Active |
| US9545434 | Treatment of short bowel syndrome patients with colon-in-continuity | 01 May, 2026 | Active |
| US9545435 | Treatment of short bowel syndrome patients with colon-in-continuity | 01 May, 2026 | Active |
| US9555079 | Treatment of short bowel syndrome patients with colon-in-continuity | 01 May, 2026 | Active |
| US9572867 | Treatment of short bowel syndrome patients with colon-in-continuity | 01 May, 2026 | Active |
| US9592273 | Treatment of short bowel syndrome patients with colon-in-continuity | 01 May, 2026 | Active |
| US9592274 | Treatment of short bowel syndrome patients with colon-in-continuity | 01 May, 2026 | Active |
| US9968655 | Treatment of short bowel syndrome patients with colon-in-continuity | 01 May, 2026 | Active |
| US9968656 | Treatment of short bowel syndrome patients with colon-in-continuity | 01 May, 2026 | Active |
| US9968658 | Treatment of short bowel syndrome patients with colon-in-continuity | 01 May, 2026 | Active |
| US9974835 | Treatment of short bowel syndrome patients with colon-in-continuity | 01 May, 2026 | Active |
| US9974837 | Treatment of short bowel syndrome patients with colon-in-continuity | 01 May, 2026 | Active |
| US9981014 | Treatment of short bowel syndrome patients with colon-in-continuity | 01 May, 2026 | Active |
| US9981016 | Treatment of short bowel syndrome patients with colon-in-continuity | 01 May, 2026 | Active |
| US9987334 | Treatment of short bowel syndrome patients with colon-in-continuity | 01 May, 2026 | Active |
| US9987335 | Treatment of short bowel syndrome patients with colon-in-continuity | 01 May, 2026 | Active |
| US9993528 | Treatment of short bowel syndrome patients with colon-in-continuity | 01 May, 2026 | Active |
| US9011926 | Method for producing granules | 24 Feb, 2026 | Active |
| US8461187 | Multiple PPI dosage form | 17 Jan, 2026 | Active |
| US9238029 | Multiple PPI dosage form | 17 Jan, 2026 | Active |
| US7847061 | Treatment of short bowel syndrome patients with colon-in-continuity | 01 Nov, 2025 | Active |
| US9060992 | Treatment of short bowel syndrome patients with colon-in-continuity | 01 Nov, 2025 | Active |
| US9539310 | Treatment of short bowel syndrome patients with colon-in-continuity | 01 Nov, 2025 | Active |
| US9545434 | Treatment of short bowel syndrome patients with colon-in-continuity | 01 Nov, 2025 | Active |
| US9545435 | Treatment of short bowel syndrome patients with colon-in-continuity | 01 Nov, 2025 | Active |
| US9555079 | Treatment of short bowel syndrome patients with colon-in-continuity | 01 Nov, 2025 | Active |
| US9572867 | Treatment of short bowel syndrome patients with colon-in-continuity | 01 Nov, 2025 | Active |
| US9592273 | Treatment of short bowel syndrome patients with colon-in-continuity | 01 Nov, 2025 | Active |
| US9592274 | Treatment of short bowel syndrome patients with colon-in-continuity | 01 Nov, 2025 | Active |
| US9968655 | Treatment of short bowel syndrome patients with colon-in-continuity | 01 Nov, 2025 | Active |
| US9968656 | Treatment of short bowel syndrome patients with colon-in-continuity | 01 Nov, 2025 | Active |
| US9968658 | Treatment of short bowel syndrome patients with colon-in-continuity | 01 Nov, 2025 | Active |
| US9974835 | Treatment of short bowel syndrome patients with colon-in-continuity | 01 Nov, 2025 | Active |
| US9974837 | Treatment of short bowel syndrome patients with colon-in-continuity | 01 Nov, 2025 | Active |
| US9981014 | Treatment of short bowel syndrome patients with colon-in-continuity | 01 Nov, 2025 | Active |
| US9981016 | Treatment of short bowel syndrome patients with colon-in-continuity | 01 Nov, 2025 | Active |
| US9987334 | Treatment of short bowel syndrome patients with colon-in-continuity | 01 Nov, 2025 | Active |
| US9987335 | Treatment of short bowel syndrome patients with colon-in-continuity | 01 Nov, 2025 | Active |
| US9993528 | Treatment of short bowel syndrome patients with colon-in-continuity | 01 Nov, 2025 | Active |
| US8173663 | Dipeptidyl peptidase inhibitors | 15 Mar, 2025 | Active |
| US8288539 | Dipeptidyl peptidase inhibitors | 15 Mar, 2025 | Active |
| US7381428 | Stabilized lanthanum carbonate compositions | 26 Aug, 2024 | Expired |
| US7465465 | Pharmaceutical formulation comprising lanthanum compounds | 26 Aug, 2024 | Expired |
| US8546608 | Proteasome inhibitors and methods of using the same | 12 Aug, 2024 | Expired |
| US9233115 | Proteasome inhibitors and methods of using the same | 12 Aug, 2024 | Expired |
| US7084245 | Peptides that bind to the erythropoietin receptor | 12 May, 2024 | Expired |
| US7414105 | Peptides that bind to the erythropoietin receptor | 12 May, 2024 | Expired |
| US7528104 | Peptides that bind to the erythropoietin receptor | 12 May, 2024 | Expired |
| US7919118 | Spacer moiety for poly (ethylene glycol) modified peptide based compounds | 12 May, 2024 | Expired |
| US8722084 | Controlled release preparation | 15 Apr, 2024 | Expired |
| US8784885 | Controlled release preparation | 15 Apr, 2024 | Expired |
| US7361676 | Solid preparation containing single crystal form | 08 Mar, 2024 | Expired |
| US8722084 | Controlled release preparation | 15 Oct, 2023 | Expired |
| US8784885 | Controlled release preparation | 15 Oct, 2023 | Expired |
| US8470368 | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative | 19 Sep, 2023 | Expired |
| US8668931 | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative | 19 Sep, 2023 | Expired |
| US9060941 | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative | 19 Sep, 2023 | Expired |
| US7105486 | Abuse-resistant amphetamine compounds | 24 Aug, 2023 | Expired |
| US7223735 | Abuse resistant lysine amphetamine compounds | 24 Aug, 2023 | Expired |
| US7655630 | Abuse-resistant amphetamine prodrugs | 24 Aug, 2023 | Expired |
| US7659253 | Abuse-resistant amphetamine prodrugs | 24 Aug, 2023 | Expired |
| US7659254 | Abuse-resistant amphetamine prodrugs | 24 Aug, 2023 | Expired |
| US7662787 | Abuse resistant lysine amphetamine compounds | 24 Aug, 2023 | Expired |
| US7662788 | Abuse-resistant amphetamine prodrugs | 24 Aug, 2023 | Expired |
| US7671030 | Abuse-resistant amphetamine prodrugs | 24 Aug, 2023 | Expired |
| US7671031 | Abuse-resistant amphetamine prodrugs | 24 Aug, 2023 | Expired |
| US7674774 | Abuse-resistant amphetamine prodrugs | 24 Aug, 2023 | Expired |
| US7678770 | Abuse-resistant amphetamine prodrugs | 24 Aug, 2023 | Expired |
| US7678771 | Abuse-resistant amphetamine prodrugs | 24 Aug, 2023 | Expired |
| US7687466 | Abuse-resistant amphetamine prodrugs | 24 Aug, 2023 | Expired |
| US7687467 | Abuse-resistant amphetamine prodrugs | 24 Aug, 2023 | Expired |
| US7700561 | Abuse-resistant amphetamine prodrugs | 24 Aug, 2023 | Expired |
| US7713936 | Abuse-resistant amphetamine prodrugs | 24 Aug, 2023 | Expired |
| US7718619 | Abuse-resistant amphetamine prodrugs | 24 Aug, 2023 | Expired |
| US7723305 | Abuse-resistant amphetamine prodrugs | 24 Aug, 2023 | Expired |
| US6664276 | Benzimidazole compound crystal | 30 Jul, 2023 | Expired |
| US7105486 | Abuse-resistant amphetamine compounds | 29 Jun, 2023 | Expired |
| US7223735 | Abuse resistant lysine amphetamine compounds | 29 Jun, 2023 | Expired |
| US7700561 | Abuse-resistant amphetamine prodrugs | 29 Jun, 2023 | Expired |
| US6913768 | Sustained release delivery of amphetamine salts | 24 May, 2023 | Expired |
| US7687467 | Abuse-resistant amphetamine prodrugs | 08 Apr, 2023 | Expired |
| US7678770 | Abuse-resistant amphetamine prodrugs | 25 Mar, 2023 | Expired |
| US7678771 | Abuse-resistant amphetamine prodrugs | 25 Mar, 2023 | Expired |
| US7056886 | GLP-2 formulations | 18 Mar, 2023 | Expired |
| US7674774 | Abuse-resistant amphetamine prodrugs | 18 Mar, 2023 | Expired |
| US7671031 | Abuse-resistant amphetamine prodrugs | 28 Feb, 2023 | Expired |
| US7655630 | Abuse-resistant amphetamine prodrugs | 24 Feb, 2023 | Expired |
| US7659253 | Abuse-resistant amphetamine prodrugs | 24 Feb, 2023 | Expired |
| US7659254 | Abuse-resistant amphetamine prodrugs | 24 Feb, 2023 | Expired |
| US7662787 | Abuse resistant lysine amphetamine compounds | 24 Feb, 2023 | Expired |
| US7662788 | Abuse-resistant amphetamine prodrugs | 24 Feb, 2023 | Expired |
| US7671030 | Abuse-resistant amphetamine prodrugs | 24 Feb, 2023 | Expired |
| US7687466 | Abuse-resistant amphetamine prodrugs | 24 Feb, 2023 | Expired |
| US7713936 | Abuse-resistant amphetamine prodrugs | 24 Feb, 2023 | Expired |
| US7718619 | Abuse-resistant amphetamine prodrugs | 24 Feb, 2023 | Expired |
| US7723305 | Abuse-resistant amphetamine prodrugs | 24 Feb, 2023 | Expired |
| US6664276 | Benzimidazole compound crystal | 30 Jan, 2023 | Expired |
| US6811794 | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles | 04 Jan, 2023 | Expired |
| US8476279 | Phenyl-piperazine derivatives as serotonin reuptake inhibitors | 02 Oct, 2022 | Expired |
| US7056886 | GLP-2 formulations | 18 Sep, 2022 | Expired |
| US6713446 | Formulation of boronic acid compounds | 25 Jul, 2022 | Expired |
| US6958319 | Formulation of boronic acid compounds | 25 Jul, 2022 | Expired |
| US6811794 | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles | 04 Jul, 2022 | Expired |
| US6713446 | Formulation of boronic acid compounds | 25 Jan, 2022 | Expired |
| US6958319 | Formulation of boronic acid compounds | 25 Jan, 2022 | Expired |
| US10098866 | Pharmaceutical preparation containing copolyvidone | 16 Nov, 2021 | Expired |
| US6287599 | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles | 20 Jun, 2021 | Expired |
| US6790459 | Methods for treating diabetes via administration of controlled release metformin | 17 Mar, 2021 | Expired |
| US6866866 | Controlled release metformin compositions | 17 Mar, 2021 | Expired |
| US6287599 | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles | 20 Dec, 2020 | Expired |
| US6462058 | Benzimidazole compound crystal | 15 Dec, 2020 | Expired |
| US6939971 | Benzimidazole compound crystal | 15 Dec, 2020 | Expired |
| US7285668 | Process for the crystallization of (R)- or (S)-lansoprazole | 15 Dec, 2020 | Expired |
| US5789379 | Glucagon-like peptide-2 analogs | 14 Oct, 2020 | Expired |
| US6462058 | Benzimidazole compound crystal | 15 Jun, 2020 | Expired |
| US6939971 | Benzimidazole compound crystal | 15 Jun, 2020 | Expired |
| US7285668 | Process for the crystallization of (R)- or (S)-lansoprazole | 15 Jun, 2020 | Expired |
| US9145389 | Benzimidazole compound crystal | 15 Jun, 2020 | Expired |
| US6773720 | Mesalazine controlled release oral pharmaceutical compositions | 08 Jun, 2020 | Expired |
| US6238994 | Method of creating a rough electrode (high surface area) from Ti and TiN and resulting article | 17 Nov, 2019 | Expired |
| US6328994 | Orally disintegrable tablets | 17 Nov, 2019 | Expired |
| US7431942 | Orally disintegrable tablets | 17 Nov, 2019 | Expired |
| US7875292 | Orally disintegrable tablets | 17 Nov, 2019 | Expired |
| US9901546 | Orally disintegrable tablets | 17 Nov, 2019 | Expired |
| US6034239 | Tricyclic compounds, their production and use | 22 Jul, 2019 | Expired |
| US6225474 | Polymorphs of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and method of producing the same | 18 Jun, 2019 | Expired |
| US6238994 | Method of creating a rough electrode (high surface area) from Ti and TiN and resulting article | 17 May, 2019 | Expired |
| US6328994 | Orally disintegrable tablets | 17 May, 2019 | Expired |
| US7431942 | Orally disintegrable tablets | 17 May, 2019 | Expired |
| US7875292 | Orally disintegrable tablets | 17 May, 2019 | Expired |
| US9901546 | Orally disintegrable tablets | 17 May, 2019 | Expired |
| US6322819 | Oral pulsed dose drug delivery system | 21 Apr, 2019 | Expired |
| US6605300 | Oral pulsed dose drug delivery system | 21 Apr, 2019 | Expired |
| USRE41148 | Oral pulsed dose drug delivery system | 21 Apr, 2019 | Expired |
| USRE42096 | Oral pulsed dose drug delivery system | 21 Apr, 2019 | Expired |
| US5614520 | 2-arylthiazole derivatives and pharmaceutical composition thereof | 25 Mar, 2019 | Expired |
| US6890898 | Method of regulating glucose metabolism, and reagents related thereto | 02 Feb, 2019 | Expired |
| US7078381 | Method of regulating glucose metabolism, and reagents related thereto | 02 Feb, 2019 | Expired |
| US7459428 | Method of regulating glucose metabolism, and reagents related thereto | 02 Feb, 2019 | Expired |
| US7399485 | Rapidly Disintegrable solid preparation | 26 Nov, 2018 | Expired |
| US5968976 | Pharmaceutical composition containing selected lanthanum carbonate hydrates | 26 Oct, 2018 | Expired |
| US6322819 | Oral pulsed dose drug delivery system | 21 Oct, 2018 | Expired |
| US6605300 | Oral pulsed dose drug delivery system | 21 Oct, 2018 | Expired |
| USRE41148 | Oral pulsed dose drug delivery system | 21 Oct, 2018 | Expired |
| USRE42096 | Oral pulsed dose drug delivery system | 21 Oct, 2018 | Expired |
| US7399485 | Rapidly Disintegrable solid preparation | 26 May, 2018 | Expired |
| US6099859 | Controlled release oral tablet having a unitary core | 20 Mar, 2018 | Expired |
| US6495162 | Controlled release oral tablet having a unitary core | 20 Mar, 2018 | Expired |
| US7919116 | Controlled release metformin formulations | 20 Mar, 2018 | Expired |
| US8475841 | Controlled release metformin formulations | 20 Mar, 2018 | Expired |
| US5780454 | Boronic ester and acid compounds | 03 Nov, 2017 | Expired |
| US5780454 | Boronic ester and acid compounds | 03 May, 2017 | Expired |
| US6303661 | Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals | 24 Apr, 2017 | Expired |
| US6303640 | Pharmaceutical composition | 09 Aug, 2016 | Expired |
| US5965584 | Pharmaceutical composition | 19 Jun, 2016 | Expired |
| US6166042 | Pharmaceutical composition | 19 Jun, 2016 | Expired |
| US6166043 | Pharmaceutical composition | 19 Jun, 2016 | Expired |
| US6172090 | Pharmaceutical composition | 19 Jun, 2016 | Expired |
| US6150383 | Pharmaceutical composition | 19 Jun, 2016 | Expired |
| US6150384 | Pharmaceutical composition | 19 Jun, 2016 | Expired |
| US6211205 | Pharmaceutical composition | 19 Jun, 2016 | Expired |
| US6271243 | Pharmaceutical composition | 19 Jun, 2016 | Expired |
| US6329404 | Pharmaceutical composition | 19 Jun, 2016 | Expired |
| US7538125 | Pharmaceutical composition | 19 Jun, 2016 | Expired |
| US5912013 | Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine | 15 Jun, 2016 | Expired |
| US5854290 | Use of guanfacine in the treatment of behavioral disorders | 21 Mar, 2016 | Expired |
| US5854290 | Use of guanfacine in the treatment of behavioral disorders | 21 Sep, 2015 | Expired |
| US5789379 | Glucagon-like peptide-2 analogs | 14 Apr, 2015 | Expired |
| US6083903 | Boronic ester and acid compounds, synthesis and uses | 28 Oct, 2014 | Expired |
| US6297217 | Boronic ester and acid compounds, synthesis and uses | 28 Oct, 2014 | Expired |
| US6617317 | Boronic ester and acid compositions | 28 Oct, 2014 | Expired |
| US6747150 | Boronic ester and acid compounds, synthesis and uses | 28 Oct, 2014 | Expired |
| US7119080 | Boronic ester and acid compounds, synthesis and uses | 28 Oct, 2014 | Expired |
| US5648333 | Peptides having bradykinin antagonist action | 15 Jul, 2014 | Expired |
| US5464632 | Rapidly disintegratable multiparticular tablet | 07 May, 2013 | Expired |
| US5464632 | Rapidly disintegratable multiparticular tablet | 07 Nov, 2012 | Expired |
Latest Legal Activities on Takeda Pharms Usa's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Takeda Pharms Usa.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Letter from FDA or Dept of Agriculture re PTE application | 15 Jul, 2024 | US9796712 |
| Letter from FDA or Dept of Agriculture re PTE application | 15 Jul, 2024 | US10227342 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 04 Jun, 2024 | US8324192 |
| Second letter to regulating agency to determine regulatory review period | 26 Apr, 2024 | US7829574 |
| Second letter to regulating agency to determine regulatory review period | 26 Apr, 2024 | US10519142 |
| Second letter to regulating agency to determine regulatory review period | 26 Apr, 2024 | US11046674 |
| Second letter to regulating agency to determine regulatory review period | 26 Apr, 2024 | US8212033 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 18 Apr, 2024 | US9493470 |
| Letter from FDA or Dept of Agriculture re PTE application | 17 Apr, 2024 | US10519142 |
| Letter from FDA or Dept of Agriculture re PTE application | 17 Apr, 2024 | US7829574 |
| Letter from FDA or Dept of Agriculture re PTE application | 17 Apr, 2024 | US8212033 |
| Letter from FDA or Dept of Agriculture re PTE application | 17 Apr, 2024 | US11046674 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 20 Mar, 2024 | US8288539 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 20 Mar, 2024 | US8288539 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 20 Mar, 2024 | US8288539 |
Takeda Pharms Usa's Drug Patent Litigations
Takeda Pharms Usa's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Apr 01, 2015, against patent number US6773720. The petitioner Coalition For Affordable Drugs II LLC, challenged the validity of this patent, with Cosmo Technologies Ltd. et al. as the respondent. Click below to track the latest information on how companies are challenging Takeda Pharms Usa's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US8846100 | December, 2017 |
FWD Entered
(03 Jul, 2019)
| Shire LLC | KVK-Tech, Inc. |
| US9173857 | December, 2017 |
FWD Entered
(03 Jul, 2019)
| Shire, LLC | KVK-Tech, Inc. |
| US6866866 | June, 2017 |
FWD Entered
(28 Dec, 2018)
| Andrx Labs, LLC | Aurobindo Pharma USA Inc. |
| US6790459 | January, 2018 |
Terminated-Denied
(05 Sep, 2018)
| Andrx Labs, LLC | Aurobindo Pharma USA Inc. |
| US6790459 | June, 2017 |
Terminated-Denied
(29 Dec, 2017)
| Andrx Labs, LLC | Aurobindo Pharma USA Inc. |
| US8846100 | January, 2017 |
Terminated-Settled
(02 May, 2017)
| Shire, LLC | Amerigen Pharmaceuticals Limited |
| US7056886 | April, 2015 |
Final Written Decision
(21 Oct, 2016)
| NPS Pharmaceuticals, Inc. et al. | Coalition for Affordable Drugs II LLC |
| US7056886 | April, 2015 |
Final Written Decision
(21 Oct, 2016)
| NPS Pharmaceuticals, Inc. et al. | Coalition for Affordable Drugs II, LLC |
| US6773720 | April, 2015 |
Final Written Decision
(05 Oct, 2016)
| Cosmo Technologies Ltd. et al. | Coalition For Affordable Drugs II LLC |
Takeda Pharms Usa Drug Patents' Oppositions Filed in EPO
Takeda Pharms Usa drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jan 02, 2009, by Teva Pharmaceutical Industries Ltd.. This opposition was filed on patent number EP00937235A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP16157001A | Aug, 2019 | Generics [UK] Ltd | Granted and Under Opposition |
| EP16157001A | Aug, 2019 | KRKA, d.d., Novo mesto | Granted and Under Opposition |
| EP16157001A | Aug, 2019 | Dr. Reddy's Laboratories Limited | Granted and Under Opposition |
| EP16157001A | Aug, 2019 | Accord Healthcare | Granted and Under Opposition |
| EP16157001A | Aug, 2019 | Zentiva k.s. | Granted and Under Opposition |
| EP16157001A | Aug, 2019 | PENTAFARMA, Sociedade Técnico-Medicinal, SA | Granted and Under Opposition |
| EP16157001A | Aug, 2019 | Synthon BV | Granted and Under Opposition |
| EP16157001A | Aug, 2019 | LEK Pharmaceuticals d.d. | Granted and Under Opposition |
| EP16157001A | Aug, 2019 | Pfizer Inc. | Granted and Under Opposition |
| EP16157001A | Jun, 2019 | Fresenius Kabi Deutschland GmbH | Granted and Under Opposition |
| EP16157001A | May, 2019 | Teva Pharmaceutical Industries Ltd. | Granted and Under Opposition |
| EP09751617A | Jun, 2018 | Generics (UK) Ltd | Granted and Under Opposition |
| EP14167982A | Mar, 2017 | Natco Pharma Limited | Revoked |
| EP13191414A | Jan, 2017 | Generics (U.K.) Limited (trading as Mylan) | Revoked |
| EP10006835A | Dec, 2016 | Generics (U.K.) Limited | Granted and Under Opposition |
| EP10006835A | Dec, 2016 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
| EP10006835A | Dec, 2016 | Fresenius Medical Care AG & Co. KGaA | Granted and Under Opposition |
| EP10006835A | Dec, 2016 | PENTAFARMA, Sociedade Técnico-Medicinal, SA | Granted and Under Opposition |
| EP10006835A | Dec, 2016 | LEK Pharmaceuticals d.d. | Granted and Under Opposition |
| EP10006835A | Dec, 2016 | Synthon Biopharmaceuticals B.V. | Granted and Under Opposition |
| EP10006835A | Dec, 2016 | Accord Healthcare | Granted and Under Opposition |
| EP10006835A | Dec, 2016 | HGF Limited | Granted and Under Opposition |
| EP10006835A | Dec, 2016 | Pfizer Inc. | Granted and Under Opposition |
| EP10175046A | Jun, 2016 | Aechter, Bernd | Patent maintained as amended |
| EP09767050A | Jan, 2016 | Generics (U.K.) Limited | Granted and Under Opposition |
| EP09767050A | Jan, 2016 | Actavis PTC ehf | Granted and Under Opposition |
| EP09767050A | Jan, 2016 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
| EP11758053A | Aug, 2015 | FRKelly | Revoked |
| EP11758053A | Aug, 2015 | Dr. Reddy's Laboratories (UK) Limited/ betapharm Arzneimittel GmbH | Revoked |
| EP11758053A | Aug, 2015 | STADA Arzneimittel AG | Revoked |
| EP11758053A | Aug, 2015 | Actavis PTC ehf | Revoked |
| EP11758053A | Aug, 2015 | Strawman Limited | Revoked |
| EP11758053A | Aug, 2015 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Revoked |
| EP03751344A | Jul, 2014 | Generics [UK] Limited | Patent maintained as amended |
| EP03751344A | Jul, 2014 | Dr Klusmann Peter | Patent maintained as amended |
| EP03754116A | Dec, 2013 | Sanovel IIaç San. ve Tic. A.S. | Patent maintained as amended |
| EP07811087A | Apr, 2013 | Cephalon, Inc. | Opposition procedure closed |
| EP04753925A | Nov, 2012 | Hexal AG | Patent maintained as amended |
| EP04753925A | Nov, 2012 | JOHNSON MATTHEY PUBLIC LIMITED COMPANY | Patent maintained as amended |
| EP04753925A | Nov, 2012 | Generics [UK] Limited | Patent maintained as amended |
| EP07764495A | Oct, 2012 | Sandoz AG | Patent maintained as amended |
| EP08850935A | Sep, 2012 | SANDOZ AG | Patent maintained as amended |
| EP02709145A | Dec, 2011 | Accord Healthcare, Ltd | Revoked |
| EP02709145A | Dec, 2011 | STADA Arzneimittel AG | Revoked |
| EP02709145A | Dec, 2011 | LEK Pharmaceuticals d.d. | Revoked |
| EP02709145A | Dec, 2011 | hameln rds gmbh | Revoked |
| EP02709145A | Dec, 2011 | Deva Holding Anonim Sirketi | Revoked |
| EP02709145A | Dec, 2011 | Synthon B.V. | Revoked |
| EP02709145A | Dec, 2011 | Actavis group PTC ehf | Revoked |
| EP04761727A | Dec, 2010 | Actavis Group PTC EHF | Opposition rejected |
| EP04761727A | Dec, 2010 | Teva Pharmaceutical Industries Ltd. | Opposition rejected |
| EP04786507A | May, 2010 | Millennium Pharmaceuticals, Inc. | Patent maintained as amended |
| EP00937235A | Jan, 2009 | Teva Pharmaceutical Industries Ltd. | Opposition procedure closed |
Takeda Pharms Usa's Family Patents
Takeda Pharms Usa drugs have patent protection in a total of 61 countries. It's US patent count contributes only to 44.0% of its total global patent coverage. 8 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Takeda Pharms Usa Drug List
Given below is the complete list of Takeda Pharms Usa's drugs and the patents protecting them.
1. Actoplus Met
Actoplus Met is protected by 6 patents, out of which 4 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9320714 | Tablet |
03 Feb, 2029
(4 years from now)
| Active |
| US9101660 | Solid preparation |
22 Jan, 2027
(2 years from now)
| Active |
| US5965584 | Pharmaceutical composition |
19 Jun, 2016
(8 years ago)
| Expired |
| US6166042 | Pharmaceutical composition |
19 Jun, 2016
(8 years ago)
| Expired |
| US6166043 | Pharmaceutical composition |
19 Jun, 2016
(8 years ago)
| Expired |
| US6172090 | Pharmaceutical composition |
19 Jun, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Actoplus Met's drug page
2. Actoplus Met Xr
Actoplus Met Xr is protected by 15 patents, out of which 13 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7785627 | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
31 Jul, 2026
(1 year, 8 months from now)
| Active |
| US7959946 | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
31 Jul, 2026
(1 year, 8 months from now)
| Active |
| US8470368 | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
19 Sep, 2023
(1 year, 1 month ago)
| Expired |
| US8668931 | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
19 Sep, 2023
(1 year, 1 month ago)
| Expired |
| US9060941 | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
19 Sep, 2023
(1 year, 1 month ago)
| Expired |
| US6790459 | Methods for treating diabetes via administration of controlled release metformin |
17 Mar, 2021
(3 years ago)
| Expired |
| US6866866 | Controlled release metformin compositions |
17 Mar, 2021
(3 years ago)
| Expired |
| US6099859 | Controlled release oral tablet having a unitary core |
20 Mar, 2018
(6 years ago)
| Expired |
| US6495162 | Controlled release oral tablet having a unitary core |
20 Mar, 2018
(6 years ago)
| Expired |
| US7919116 | Controlled release metformin formulations |
20 Mar, 2018
(6 years ago)
| Expired |
| US8475841 | Controlled release metformin formulations |
20 Mar, 2018
(6 years ago)
| Expired |
| US5965584 | Pharmaceutical composition |
19 Jun, 2016
(8 years ago)
| Expired |
| US6166042 | Pharmaceutical composition |
19 Jun, 2016
(8 years ago)
| Expired |
| US6166043 | Pharmaceutical composition |
19 Jun, 2016
(8 years ago)
| Expired |
| US6172090 | Pharmaceutical composition |
19 Jun, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Actoplus Met Xr's drug page
3. Actos
Actos is protected by 10 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6303640 | Pharmaceutical composition |
09 Aug, 2016
(8 years ago)
| Expired |
| US5965584 | Pharmaceutical composition |
19 Jun, 2016
(8 years ago)
| Expired |
| US6150383 | Pharmaceutical composition |
19 Jun, 2016
(8 years ago)
| Expired |
| US6150384 | Pharmaceutical composition |
19 Jun, 2016
(8 years ago)
| Expired |
| US6166042 | Pharmaceutical composition |
19 Jun, 2016
(8 years ago)
| Expired |
| US6166043 | Pharmaceutical composition |
19 Jun, 2016
(8 years ago)
| Expired |
| US6172090 | Pharmaceutical composition |
19 Jun, 2016
(8 years ago)
| Expired |
| US6211205 | Pharmaceutical composition |
19 Jun, 2016
(8 years ago)
| Expired |
| US6271243 | Pharmaceutical composition |
19 Jun, 2016
(8 years ago)
| Expired |
| US6329404 | Pharmaceutical composition |
19 Jun, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Actos's drug page
4. Adderall Xr 10
Adderall Xr 10 is protected by 8 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6322819
(Pediatric)
| Oral pulsed dose drug delivery system |
21 Apr, 2019
(5 years ago)
| Expired |
| US6605300
(Pediatric)
| Oral pulsed dose drug delivery system |
21 Apr, 2019
(5 years ago)
| Expired |
| USRE41148
(Pediatric)
| Oral pulsed dose drug delivery system |
21 Apr, 2019
(5 years ago)
| Expired |
| USRE42096
(Pediatric)
| Oral pulsed dose drug delivery system |
21 Apr, 2019
(5 years ago)
| Expired |
| US6322819 | Oral pulsed dose drug delivery system |
21 Oct, 2018
(6 years ago)
| Expired |
| US6605300 | Oral pulsed dose drug delivery system |
21 Oct, 2018
(6 years ago)
| Expired |
| USRE41148 | Oral pulsed dose drug delivery system |
21 Oct, 2018
(6 years ago)
| Expired |
| USRE42096 | Oral pulsed dose drug delivery system |
21 Oct, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Adderall Xr 10's drug page
5. Adderall Xr 15
Adderall Xr 15 is protected by 8 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6322819
(Pediatric)
| Oral pulsed dose drug delivery system |
21 Apr, 2019
(5 years ago)
| Expired |
| US6605300
(Pediatric)
| Oral pulsed dose drug delivery system |
21 Apr, 2019
(5 years ago)
| Expired |
| USRE41148
(Pediatric)
| Oral pulsed dose drug delivery system |
21 Apr, 2019
(5 years ago)
| Expired |
| USRE42096
(Pediatric)
| Oral pulsed dose drug delivery system |
21 Apr, 2019
(5 years ago)
| Expired |
| US6322819 | Oral pulsed dose drug delivery system |
21 Oct, 2018
(6 years ago)
| Expired |
| US6605300 | Oral pulsed dose drug delivery system |
21 Oct, 2018
(6 years ago)
| Expired |
| USRE41148 | Oral pulsed dose drug delivery system |
21 Oct, 2018
(6 years ago)
| Expired |
| USRE42096 | Oral pulsed dose drug delivery system |
21 Oct, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Adderall Xr 15's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
6. Adderall Xr 20
Adderall Xr 20 is protected by 8 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6322819
(Pediatric)
| Oral pulsed dose drug delivery system |
21 Apr, 2019
(5 years ago)
| Expired |
| US6605300
(Pediatric)
| Oral pulsed dose drug delivery system |
21 Apr, 2019
(5 years ago)
| Expired |
| USRE41148
(Pediatric)
| Oral pulsed dose drug delivery system |
21 Apr, 2019
(5 years ago)
| Expired |
| USRE42096
(Pediatric)
| Oral pulsed dose drug delivery system |
21 Apr, 2019
(5 years ago)
| Expired |
| US6322819 | Oral pulsed dose drug delivery system |
21 Oct, 2018
(6 years ago)
| Expired |
| US6605300 | Oral pulsed dose drug delivery system |
21 Oct, 2018
(6 years ago)
| Expired |
| USRE41148 | Oral pulsed dose drug delivery system |
21 Oct, 2018
(6 years ago)
| Expired |
| USRE42096 | Oral pulsed dose drug delivery system |
21 Oct, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Adderall Xr 20's drug page
7. Adderall Xr 25
Adderall Xr 25 is protected by 8 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6322819
(Pediatric)
| Oral pulsed dose drug delivery system |
21 Apr, 2019
(5 years ago)
| Expired |
| US6605300
(Pediatric)
| Oral pulsed dose drug delivery system |
21 Apr, 2019
(5 years ago)
| Expired |
| USRE41148
(Pediatric)
| Oral pulsed dose drug delivery system |
21 Apr, 2019
(5 years ago)
| Expired |
| USRE42096
(Pediatric)
| Oral pulsed dose drug delivery system |
21 Apr, 2019
(5 years ago)
| Expired |
| US6322819 | Oral pulsed dose drug delivery system |
21 Oct, 2018
(6 years ago)
| Expired |
| US6605300 | Oral pulsed dose drug delivery system |
21 Oct, 2018
(6 years ago)
| Expired |
| USRE41148 | Oral pulsed dose drug delivery system |
21 Oct, 2018
(6 years ago)
| Expired |
| USRE42096 | Oral pulsed dose drug delivery system |
21 Oct, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Adderall Xr 25's drug page
8. Adderall Xr 30
Adderall Xr 30 is protected by 8 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6322819
(Pediatric)
| Oral pulsed dose drug delivery system |
21 Apr, 2019
(5 years ago)
| Expired |
| US6605300
(Pediatric)
| Oral pulsed dose drug delivery system |
21 Apr, 2019
(5 years ago)
| Expired |
| USRE41148
(Pediatric)
| Oral pulsed dose drug delivery system |
21 Apr, 2019
(5 years ago)
| Expired |
| USRE42096
(Pediatric)
| Oral pulsed dose drug delivery system |
21 Apr, 2019
(5 years ago)
| Expired |
| US6322819 | Oral pulsed dose drug delivery system |
21 Oct, 2018
(6 years ago)
| Expired |
| US6605300 | Oral pulsed dose drug delivery system |
21 Oct, 2018
(6 years ago)
| Expired |
| USRE41148 | Oral pulsed dose drug delivery system |
21 Oct, 2018
(6 years ago)
| Expired |
| USRE42096 | Oral pulsed dose drug delivery system |
21 Oct, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Adderall Xr 30's drug page
9. Adderall Xr 5
Adderall Xr 5 is protected by 8 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6322819
(Pediatric)
| Oral pulsed dose drug delivery system |
21 Apr, 2019
(5 years ago)
| Expired |
| US6605300
(Pediatric)
| Oral pulsed dose drug delivery system |
21 Apr, 2019
(5 years ago)
| Expired |
| USRE41148
(Pediatric)
| Oral pulsed dose drug delivery system |
21 Apr, 2019
(5 years ago)
| Expired |
| USRE42096
(Pediatric)
| Oral pulsed dose drug delivery system |
21 Apr, 2019
(5 years ago)
| Expired |
| US6322819 | Oral pulsed dose drug delivery system |
21 Oct, 2018
(6 years ago)
| Expired |
| US6605300 | Oral pulsed dose drug delivery system |
21 Oct, 2018
(6 years ago)
| Expired |
| USRE41148 | Oral pulsed dose drug delivery system |
21 Oct, 2018
(6 years ago)
| Expired |
| USRE42096 | Oral pulsed dose drug delivery system |
21 Oct, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Adderall Xr 5's drug page
10. Alunbrig
Alunbrig is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10385078 | Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-YL) piperidin-1-YL]phenyl}pyrimidine-2,4-diamine |
10 Nov, 2035
(10 years from now)
| Active |
| US9611283 | Methods for inhibiting cell proliferation in ALK-driven cancers |
10 Apr, 2034
(9 years from now)
| Active |
| US9012462 | Phosphorous derivatives as kinase inhibitors |
28 Apr, 2031
(6 years from now)
| Active |
| US9273077 | Phosphorus derivatives as kinase inhibitors |
21 May, 2029
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Alunbrig's drug page
11. Carbatrol
Carbatrol is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5912013 | Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine |
15 Jun, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Carbatrol's drug page
12. Colcrys
Colcrys is protected by 17 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7820681 | Methods for concomitant administration of colchicine and a second active agent |
17 Feb, 2029
(4 years from now)
| Active |
| US7906519 | Methods for concomitant administration of colchicine and a second active agent |
17 Feb, 2029
(4 years from now)
| Active |
| US7915269 | Methods for concomitant administration of colchicine and a second active agent |
17 Feb, 2029
(4 years from now)
| Active |
| US8440721 | Methods for concomitant administration of colchicine and a second active agent |
17 Feb, 2029
(4 years from now)
| Active |
| US8440722 | Methods for concomitant administration of colchicine and a second active agent |
17 Feb, 2029
(4 years from now)
| Active |
| US7601758 | Methods for concomitant administration of colchicine and macrolide antibiotics in the treatment of gout flares |
10 Feb, 2029
(4 years from now)
| Active |
| US7619004 | Methods for concomitant administration of colchicine and macrolide antibiotics |
03 Dec, 2028
(4 years from now)
| Active |
| US7935731 | Methods for concomitant administration of colchicine and macrolide antibiotics |
03 Dec, 2028
(4 years from now)
| Active |
| US7964647 | Colchicine compositions and methods |
06 Oct, 2028
(3 years from now)
| Active |
| US7964648 | Methods for concomitant administration of colchicine and a second active agent |
06 Oct, 2028
(3 years from now)
| Active |
| US7981938 | Colchicine compositions and methods |
06 Oct, 2028
(3 years from now)
| Active |
| US8093296 | Methods for concomitant administration of colchicine and macrolide antibiotics |
06 Oct, 2028
(3 years from now)
| Active |
| US8093297 | Methods for concomitant administration of colchicine and a second active agent |
06 Oct, 2028
(3 years from now)
| Active |
| US8093298 | Methods for concomitant administration of colchicine and macrolide antibiotics |
06 Oct, 2028
(3 years from now)
| Active |
| US8097655 | Methods for concomitant administration of colchicine and macrolide antibiotics |
06 Oct, 2028
(3 years from now)
| Active |
| US8415395 | Colchicine compositions and methods |
06 Oct, 2028
(3 years from now)
| Active |
| US8415396 | Colchine compositions and methods |
06 Oct, 2028
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Colcrys's drug page
13. Dexilant
Dexilant is protected by 25 patents, out of which 13 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9233103 | Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy |
05 Mar, 2032
(7 years from now)
| Active |
| US8173158
(Pediatric)
| Methods of treating gastrointestinal disorders independent of the intake of food |
17 Sep, 2030
(5 years from now)
| Active |
| US8173158 | Methods of treating gastrointestinal disorders independent of the intake of food |
17 Mar, 2030
(5 years from now)
| Active |
| US8871273 | Method for producing granules |
11 Jan, 2028
(3 years from now)
| Active |
| US8105626
(Pediatric)
| Granules containing acid-unstable chemical in large amount |
27 Mar, 2027
(2 years from now)
| Active |
| US7790755
(Pediatric)
| Controlled release preparation |
02 Feb, 2027
(2 years from now)
| Active |
| US8105626 | Granules containing acid-unstable chemical in large amount |
27 Sep, 2026
(1 year, 10 months from now)
| Active |
| US7790755 | Controlled release preparation |
02 Aug, 2026
(1 year, 8 months from now)
| Active |
| US8461187
(Pediatric)
| Multiple PPI dosage form |
17 Jul, 2026
(1 year, 7 months from now)
| Active |
| US9011926 | Method for producing granules |
24 Feb, 2026
(1 year, 3 months from now)
| Active |
| US8461187 | Multiple PPI dosage form |
17 Jan, 2026
(1 year, 2 months from now)
| Active |
| US9238029 | Multiple PPI dosage form |
17 Jan, 2026
(1 year, 2 months from now)
| Active |
| US8722084
(Pediatric)
| Controlled release preparation |
15 Apr, 2024
(7 months ago)
| Expired |
| US8784885
(Pediatric)
| Controlled release preparation |
15 Apr, 2024
(7 months ago)
| Expired |
| US8722084 | Controlled release preparation |
15 Oct, 2023
(1 year, 1 month ago)
| Expired |
| US8784885 | Controlled release preparation |
15 Oct, 2023
(1 year, 1 month ago)
| Expired |
| US6462058
(Pediatric)
| Benzimidazole compound crystal |
15 Dec, 2020
(3 years ago)
| Expired |
| US6664276
(Pediatric)
| Benzimidazole compound crystal |
15 Dec, 2020
(3 years ago)
| Expired |
| US6939971
(Pediatric)
| Benzimidazole compound crystal |
15 Dec, 2020
(3 years ago)
| Expired |
| US7285668
(Pediatric)
| Process for the crystallization of (R)- or (S)-lansoprazole |
15 Dec, 2020
(3 years ago)
| Expired |
| US6462058 | Benzimidazole compound crystal |
15 Jun, 2020
(4 years ago)
| Expired |
| US6664276 | Benzimidazole compound crystal |
15 Jun, 2020
(4 years ago)
| Expired |
| US6939971 | Benzimidazole compound crystal |
15 Jun, 2020
(4 years ago)
| Expired |
| US7285668 | Process for the crystallization of (R)- or (S)-lansoprazole |
15 Jun, 2020
(4 years ago)
| Expired |
| US9145389 | Benzimidazole compound crystal |
15 Jun, 2020
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Dexilant's drug page
14. Dexilant Solutab
Dexilant Solutab is protected by 28 patents, out of which 21 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9241910 | Orally-disintegrating solid preparation |
10 Mar, 2029
(4 years from now)
| Active |
| US8871273
(Pediatric)
| Method for producing granules |
11 Jul, 2028
(3 years from now)
| Active |
| US8871273 | Method for producing granules |
11 Jan, 2028
(3 years from now)
| Active |
| US8461187
(Pediatric)
| Multiple PPI dosage form |
17 Jul, 2026
(1 year, 7 months from now)
| Active |
| US9011926 | Method for producing granules |
24 Feb, 2026
(1 year, 3 months from now)
| Active |
| US8461187 | Multiple PPI dosage form |
17 Jan, 2026
(1 year, 2 months from now)
| Active |
| US9238029 | Multiple PPI dosage form |
17 Jan, 2026
(1 year, 2 months from now)
| Active |
| US8784885
(Pediatric)
| Controlled release preparation |
15 Apr, 2024
(7 months ago)
| Expired |
| US8784885 | Controlled release preparation |
15 Oct, 2023
(1 year, 1 month ago)
| Expired |
| US6664276
(Pediatric)
| Benzimidazole compound crystal |
30 Jul, 2023
(1 year, 3 months ago)
| Expired |
| US6664276 | Benzimidazole compound crystal |
30 Jan, 2023
(1 year, 9 months ago)
| Expired |
| US6462058
(Pediatric)
| Benzimidazole compound crystal |
15 Dec, 2020
(3 years ago)
| Expired |
| US6939971
(Pediatric)
| Benzimidazole compound crystal |
15 Dec, 2020
(3 years ago)
| Expired |
| US7285668
(Pediatric)
| Process for the crystallization of (R)- or (S)-lansoprazole |
15 Dec, 2020
(3 years ago)
| Expired |
| US6462058 | Benzimidazole compound crystal |
15 Jun, 2020
(4 years ago)
| Expired |
| US6939971 | Benzimidazole compound crystal |
15 Jun, 2020
(4 years ago)
| Expired |
| US7285668 | Process for the crystallization of (R)- or (S)-lansoprazole |
15 Jun, 2020
(4 years ago)
| Expired |
| US9145389 | Benzimidazole compound crystal |
15 Jun, 2020
(4 years ago)
| Expired |
| US6238994
(Pediatric)
| Method of creating a rough electrode (high surface area) from Ti and TiN and resulting article |
17 Nov, 2019
(5 years ago)
| Expired |
| US6328994
(Pediatric)
| Orally disintegrable tablets |
17 Nov, 2019
(5 years ago)
| Expired |
| US7431942
(Pediatric)
| Orally disintegrable tablets |
17 Nov, 2019
(5 years ago)
| Expired |
| US7875292
(Pediatric)
| Orally disintegrable tablets |
17 Nov, 2019
(5 years ago)
| Expired |
| US6238994 | Method of creating a rough electrode (high surface area) from Ti and TiN and resulting article |
17 May, 2019
(5 years ago)
| Expired |
| US6328994 | Orally disintegrable tablets |
17 May, 2019
(5 years ago)
| Expired |
| US7431942 | Orally disintegrable tablets |
17 May, 2019
(5 years ago)
| Expired |
| US7875292 | Orally disintegrable tablets |
17 May, 2019
(5 years ago)
| Expired |
| US7399485
(Pediatric)
| Rapidly Disintegrable solid preparation |
26 Nov, 2018
(5 years ago)
| Expired |
| US7399485 | Rapidly Disintegrable solid preparation |
26 May, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Dexilant Solutab's drug page
15. Duetact
Duetact is protected by 7 patents, out of which 5 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8071130 | Solid preparation |
08 Jun, 2028
(3 years from now)
| Active |
| US7700128 | Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester |
30 Jan, 2027
(2 years from now)
| Active |
| US6303640 | Pharmaceutical composition |
09 Aug, 2016
(8 years ago)
| Expired |
| US6150383 | Pharmaceutical composition |
19 Jun, 2016
(8 years ago)
| Expired |
| US6211205 | Pharmaceutical composition |
19 Jun, 2016
(8 years ago)
| Expired |
| US6329404 | Pharmaceutical composition |
19 Jun, 2016
(8 years ago)
| Expired |
| US7538125 | Pharmaceutical composition |
19 Jun, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Duetact's drug page
16. Eohilia
Eohilia is protected by 12 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11260064 | Stable corticosteroid compositions |
10 Jan, 2039
(14 years from now)
| Active |
| US11564934 | Stable corticosteroid compositions |
10 Jan, 2039
(14 years from now)
| Active |
| US8324192 | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
03 Aug, 2029
(4 years from now)
| Active |
| US9050368 | Corticosteroid compositions |
01 Aug, 2029
(4 years from now)
| Active |
| US10293052 | Compositions for the treatment of gastrointestinal inflammation |
22 Nov, 2028
(4 years from now)
| Active |
| US11357859 | Compositions for the treatment of gastrointestinal inflammation |
12 Nov, 2028
(3 years from now)
| Active |
| US11197822 | Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract |
09 Nov, 2026
(1 year, 11 months from now)
| Active |
| US11413296 | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
09 Nov, 2026
(1 year, 11 months from now)
| Active |
| US8497258 | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
09 Nov, 2026
(1 year, 11 months from now)
| Active |
| US8679545 | Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract |
09 Nov, 2026
(1 year, 11 months from now)
| Active |
| US8975243 | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
09 Nov, 2026
(1 year, 11 months from now)
| Active |
| US9119863 | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
09 Nov, 2026
(1 year, 11 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Eohilia's drug page
17. Exkivity
Exkivity is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10227342 | Heteroaryl compounds for kinase inhibition |
13 May, 2035
(10 years from now)
| Active |
| US9796712 | Heteroaryl compounds for kinase inhibition |
13 May, 2035
(10 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Exkivity's drug page
18. Firazyr
Firazyr is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5648333 | Peptides having bradykinin antagonist action |
15 Jul, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Firazyr's drug page
19. Fosrenol
Fosrenol is protected by 5 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8980327 | Capsule and powder formulations containing lanthanum compounds |
01 Dec, 2030
(6 years from now)
| Active |
| US9023397 | Capsule and powder formulations containing lanthanum compounds |
01 Dec, 2030
(6 years from now)
| Active |
| US7381428 | Stabilized lanthanum carbonate compositions |
26 Aug, 2024
(2 months ago)
| Expired |
| US7465465 | Pharmaceutical formulation comprising lanthanum compounds |
26 Aug, 2024
(2 months ago)
| Expired |
| US5968976 | Pharmaceutical composition containing selected lanthanum carbonate hydrates |
26 Oct, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Fosrenol's drug page
20. Fruzaqla
Fruzaqla is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10519142 | Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide |
07 Sep, 2035
(10 years from now)
| Active |
| US11046674 | Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide |
07 Sep, 2035
(10 years from now)
| Active |
| US7829574 | Substituted quinazoline compounds and their use in treating angiogenesis-related diseases |
09 May, 2028
(3 years from now)
| Active |
| US8212033 | Use of substituted quinazoline compounds in treating angiogenesis-related diseases |
09 May, 2028
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Fruzaqla's drug page
21. Gattex Kit
Gattex Kit is protected by 42 patents, out of which 4 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7847061
(Pediatric)
| Treatment of short bowel syndrome patients with colon-in-continuity |
01 May, 2026
(1 year, 5 months from now)
| Active |
| US9060992
(Pediatric)
| Treatment of short bowel syndrome patients with colon-in-continuity |
01 May, 2026
(1 year, 5 months from now)
| Active |
| US9539310
(Pediatric)
| Treatment of short bowel syndrome patients with colon-in-continuity |
01 May, 2026
(1 year, 5 months from now)
| Active |
| US9545434
(Pediatric)
| Treatment of short bowel syndrome patients with colon-in-continuity |
01 May, 2026
(1 year, 5 months from now)
| Active |
| US9545435
(Pediatric)
| Treatment of short bowel syndrome patients with colon-in-continuity |
01 May, 2026
(1 year, 5 months from now)
| Active |
| US9555079
(Pediatric)
| Treatment of short bowel syndrome patients with colon-in-continuity |
01 May, 2026
(1 year, 5 months from now)
| Active |
| US9572867
(Pediatric)
| Treatment of short bowel syndrome patients with colon-in-continuity |
01 May, 2026
(1 year, 5 months from now)
| Active |
| US9592273
(Pediatric)
| Treatment of short bowel syndrome patients with colon-in-continuity |
01 May, 2026
(1 year, 5 months from now)
| Active |
| US9592274
(Pediatric)
| Treatment of short bowel syndrome patients with colon-in-continuity |
01 May, 2026
(1 year, 5 months from now)
| Active |
| US9968655
(Pediatric)
| Treatment of short bowel syndrome patients with colon-in-continuity |
01 May, 2026
(1 year, 5 months from now)
| Active |
| US9968656
(Pediatric)
| Treatment of short bowel syndrome patients with colon-in-continuity |
01 May, 2026
(1 year, 5 months from now)
| Active |
| US9968658
(Pediatric)
| Treatment of short bowel syndrome patients with colon-in-continuity |
01 May, 2026
(1 year, 5 months from now)
| Active |
| US9974835
(Pediatric)
| Treatment of short bowel syndrome patients with colon-in-continuity |
01 May, 2026
(1 year, 5 months from now)
| Active |
| US9974837
(Pediatric)
| Treatment of short bowel syndrome patients with colon-in-continuity |
01 May, 2026
(1 year, 5 months from now)
| Active |
| US9981014
(Pediatric)
| Treatment of short bowel syndrome patients with colon-in-continuity |
01 May, 2026
(1 year, 5 months from now)
| Active |
| US9981016
(Pediatric)
| Treatment of short bowel syndrome patients with colon-in-continuity |
01 May, 2026
(1 year, 5 months from now)
| Active |
| US9987334
(Pediatric)
| Treatment of short bowel syndrome patients with colon-in-continuity |
01 May, 2026
(1 year, 5 months from now)
| Active |
| US9987335
(Pediatric)
| Treatment of short bowel syndrome patients with colon-in-continuity |
01 May, 2026
(1 year, 5 months from now)
| Active |
| US9993528
(Pediatric)
| Treatment of short bowel syndrome patients with colon-in-continuity |
01 May, 2026
(1 year, 5 months from now)
| Active |
| US7847061 | Treatment of short bowel syndrome patients with colon-in-continuity |
01 Nov, 2025
(11 months from now)
| Active |
| US9060992 | Treatment of short bowel syndrome patients with colon-in-continuity |
01 Nov, 2025
(11 months from now)
| Active |
| US9539310 | Treatment of short bowel syndrome patients with colon-in-continuity |
01 Nov, 2025
(11 months from now)
| Active |
| US9545434 | Treatment of short bowel syndrome patients with colon-in-continuity |
01 Nov, 2025
(11 months from now)
| Active |
| US9545435 | Treatment of short bowel syndrome patients with colon-in-continuity |
01 Nov, 2025
(11 months from now)
| Active |
| US9555079 | Treatment of short bowel syndrome patients with colon-in-continuity |
01 Nov, 2025
(11 months from now)
| Active |
| US9572867 | Treatment of short bowel syndrome patients with colon-in-continuity |
01 Nov, 2025
(11 months from now)
| Active |
| US9592273 | Treatment of short bowel syndrome patients with colon-in-continuity |
01 Nov, 2025
(11 months from now)
| Active |
| US9592274 | Treatment of short bowel syndrome patients with colon-in-continuity |
01 Nov, 2025
(11 months from now)
| Active |
| US9968655 | Treatment of short bowel syndrome patients with colon-in-continuity |
01 Nov, 2025
(11 months from now)
| Active |
| US9968656 | Treatment of short bowel syndrome patients with colon-in-continuity |
01 Nov, 2025
(11 months from now)
| Active |
| US9968658 | Treatment of short bowel syndrome patients with colon-in-continuity |
01 Nov, 2025
(11 months from now)
| Active |
| US9974835 | Treatment of short bowel syndrome patients with colon-in-continuity |
01 Nov, 2025
(11 months from now)
| Active |
| US9974837 | Treatment of short bowel syndrome patients with colon-in-continuity |
01 Nov, 2025
(11 months from now)
| Active |
| US9981014 | Treatment of short bowel syndrome patients with colon-in-continuity |
01 Nov, 2025
(11 months from now)
| Active |
| US9981016 | Treatment of short bowel syndrome patients with colon-in-continuity |
01 Nov, 2025
(11 months from now)
| Active |
| US9987334 | Treatment of short bowel syndrome patients with colon-in-continuity |
01 Nov, 2025
(11 months from now)
| Active |
| US9987335 | Treatment of short bowel syndrome patients with colon-in-continuity |
01 Nov, 2025
(11 months from now)
| Active |
| US9993528 | Treatment of short bowel syndrome patients with colon-in-continuity |
01 Nov, 2025
(11 months from now)
| Active |
| US7056886
(Pediatric)
| GLP-2 formulations |
18 Mar, 2023
(1 year, 7 months ago)
| Expired |
| US7056886 | GLP-2 formulations |
18 Sep, 2022
(2 years ago)
| Expired |
| US5789379
(Pediatric)
| Glucagon-like peptide-2 analogs |
14 Oct, 2020
(4 years ago)
| Expired |
| US5789379 | Glucagon-like peptide-2 analogs |
14 Apr, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Gattex Kit's drug page
22. Iclusig
Iclusig is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11192895 | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt |
12 Dec, 2033
(9 years from now)
| Active |
| US11192897 | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt |
12 Dec, 2033
(9 years from now)
| Active |
| US11384086 | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1- yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt |
12 Dec, 2033
(9 years from now)
| Active |
| US9493470 | Crystalline forms of 3-(imidazo[1,2-B] pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt |
12 Dec, 2033
(9 years from now)
| Active |
| US8114874 | Substituted acetylenic imidazo[1,2-B]pyridazine compounds as kinase inhibitors |
24 Jan, 2027
(2 years from now)
| Active |
| US9029533 | Substituted acetylenic imidazo[1,2-A]pyridazines as kinase inhibitors |
22 Dec, 2026
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Iclusig's drug page
23. Intuniv
Intuniv is protected by 6 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6811794
(Pediatric)
| Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
04 Jan, 2023
(1 year, 10 months ago)
| Expired |
| US6811794 | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
04 Jul, 2022
(2 years ago)
| Expired |
| US6287599
(Pediatric)
| Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
20 Jun, 2021
(3 years ago)
| Expired |
| US6287599 | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
20 Dec, 2020
(3 years ago)
| Expired |
| US5854290
(Pediatric)
| Use of guanfacine in the treatment of behavioral disorders |
21 Mar, 2016
(8 years ago)
| Expired |
| US5854290 | Use of guanfacine in the treatment of behavioral disorders |
21 Sep, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Intuniv's drug page
24. Kazano
Kazano is protected by 17 patents, out of which 13 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8900638 | Solid preparation comprising alogliptin and metformin hydrochloride |
24 May, 2029
(4 years from now)
| Active |
| US7807689 | Dipeptidyl peptidase inhibitors |
27 Jun, 2028
(3 years from now)
| Active |
| US8288539 | Dipeptidyl peptidase inhibitors |
24 Jun, 2025
(7 months from now)
| Active |
| US8173663 | Dipeptidyl peptidase inhibitors |
15 Mar, 2025
(3 months from now)
| Active |
| US6890898 | Method of regulating glucose metabolism, and reagents related thereto |
02 Feb, 2019
(5 years ago)
| Expired |
| US7078381 | Method of regulating glucose metabolism, and reagents related thereto |
02 Feb, 2019
(5 years ago)
| Expired |
| US7459428 | Method of regulating glucose metabolism, and reagents related thereto |
02 Feb, 2019
(5 years ago)
| Expired |
| US6303661 | Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals |
24 Apr, 2017
(7 years ago)
| Expired |
| US6303640 | Pharmaceutical composition |
09 Aug, 2016
(8 years ago)
| Expired |
| US5965584 | Pharmaceutical composition |
19 Jun, 2016
(8 years ago)
| Expired |
| US6150383 | Pharmaceutical composition |
19 Jun, 2016
(8 years ago)
| Expired |
| US6150384 | Pharmaceutical composition |
19 Jun, 2016
(8 years ago)
| Expired |
| US6166042 | Pharmaceutical composition |
19 Jun, 2016
(8 years ago)
| Expired |
| US6166043 | Pharmaceutical composition |
19 Jun, 2016
(8 years ago)
| Expired |
| US6172090 | Pharmaceutical composition |
19 Jun, 2016
(8 years ago)
| Expired |
| US6211205 | Pharmaceutical composition |
19 Jun, 2016
(8 years ago)
| Expired |
| US6329404 | Pharmaceutical composition |
19 Jun, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Kazano's drug page
25. Lialda
Lialda is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6773720 | Mesalazine controlled release oral pharmaceutical compositions |
08 Jun, 2020
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lialda's drug page
26. Livtencity
Livtencity is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11684632 | Maribavir isomers, compositions, methods of making and methods of using |
04 Jan, 2032
(7 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Livtencity's drug page
27. Mydayis
Mydayis is protected by 5 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8846100 | Controlled dose drug delivery system |
24 Aug, 2029
(4 years from now)
| Active |
| US9173857 | Controlled dose drug delivery system |
12 May, 2026
(1 year, 5 months from now)
| Active |
| US6913768 | Sustained release delivery of amphetamine salts |
24 May, 2023
(1 year, 5 months ago)
| Expired |
| USRE41148 | Oral pulsed dose drug delivery system |
21 Oct, 2018
(6 years ago)
| Expired |
| USRE42096 | Oral pulsed dose drug delivery system |
21 Oct, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Mydayis's drug page
28. Nesina
Nesina is protected by 12 patents, out of which 8 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8697125 | Tablet preparation without causing a tableting trouble |
16 Jun, 2029
(4 years from now)
| Active |
| US7807689 | Dipeptidyl peptidase inhibitors |
27 Jun, 2028
(3 years from now)
| Active |
| US8173663 | Dipeptidyl peptidase inhibitors |
02 Dec, 2025
(1 year, 16 days from now)
| Active |
| US8288539 | Dipeptidyl peptidase inhibitors |
15 Mar, 2025
(3 months from now)
| Active |
| US6890898 | Method of regulating glucose metabolism, and reagents related thereto |
02 Feb, 2019
(5 years ago)
| Expired |
| US7078381 | Method of regulating glucose metabolism, and reagents related thereto |
02 Feb, 2019
(5 years ago)
| Expired |
| US7459428 | Method of regulating glucose metabolism, and reagents related thereto |
02 Feb, 2019
(5 years ago)
| Expired |
| US6303661 | Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals |
24 Apr, 2017
(7 years ago)
| Expired |
| US6303640 | Pharmaceutical composition |
09 Aug, 2016
(8 years ago)
| Expired |
| US6150383 | Pharmaceutical composition |
19 Jun, 2016
(8 years ago)
| Expired |
| US6211205 | Pharmaceutical composition |
19 Jun, 2016
(8 years ago)
| Expired |
| US6329404 | Pharmaceutical composition |
19 Jun, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nesina's drug page
29. Ninlaro
Ninlaro is protected by 9 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7442830 | Proteasome inhibitors |
20 Nov, 2029
(5 years from now)
| Active |
| US8859504 | Boronate ester compounds and pharmaceutical compositions thereof |
16 Jun, 2029
(4 years from now)
| Active |
| US9175017 | Boronate ester compounds and pharmaceutical compositions thereof |
16 Jun, 2029
(4 years from now)
| Active |
| US7687662 | Proteasome inhibitors |
06 Aug, 2027
(2 years from now)
| Active |
| US8003819 | Proteasome inhibitors |
06 Aug, 2027
(2 years from now)
| Active |
| US8530694 | Proteasome inhibitors |
06 Aug, 2027
(2 years from now)
| Active |
| US8871745 | Proteasome inhibitors |
06 Aug, 2027
(2 years from now)
| Active |
| US8546608 | Proteasome inhibitors and methods of using the same |
12 Aug, 2024
(3 months ago)
| Expired |
| US9233115 | Proteasome inhibitors and methods of using the same |
12 Aug, 2024
(3 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ninlaro's drug page
30. Omontys
Omontys is protected by 6 patents, out of which 4 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7550433 | Erythropoietin receptor peptide formulations and uses |
02 Jun, 2026
(1 year, 6 months from now)
| Active |
| US7919461 | Erythropoietin receptor peptide formulations and uses |
02 Jun, 2026
(1 year, 6 months from now)
| Active |
| US7084245 | Peptides that bind to the erythropoietin receptor |
12 May, 2024
(6 months ago)
| Expired |
| US7414105 | Peptides that bind to the erythropoietin receptor |
12 May, 2024
(6 months ago)
| Expired |
| US7528104 | Peptides that bind to the erythropoietin receptor |
12 May, 2024
(6 months ago)
| Expired |
| US7919118 | Spacer moiety for poly (ethylene glycol) modified peptide based compounds |
12 May, 2024
(6 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Omontys's drug page
31. Omontys Preservative Free
Omontys Preservative Free is protected by 6 patents, out of which 4 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7550433 | Erythropoietin receptor peptide formulations and uses |
02 Jun, 2026
(1 year, 6 months from now)
| Active |
| US7919461 | Erythropoietin receptor peptide formulations and uses |
02 Jun, 2026
(1 year, 6 months from now)
| Active |
| US7084245 | Peptides that bind to the erythropoietin receptor |
12 May, 2024
(6 months ago)
| Expired |
| US7414105 | Peptides that bind to the erythropoietin receptor |
12 May, 2024
(6 months ago)
| Expired |
| US7528104 | Peptides that bind to the erythropoietin receptor |
12 May, 2024
(6 months ago)
| Expired |
| US7919118 | Spacer moiety for poly (ethylene glycol) modified peptide based compounds |
12 May, 2024
(6 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Omontys Preservative Free's drug page
32. Oseni
Oseni is protected by 18 patents, out of which 14 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8637079 | Solid preparation comprising alogliptin and pioglitazone |
04 Jun, 2029
(4 years from now)
| Active |
| US7807689 | Dipeptidyl peptidase inhibitors |
27 Jun, 2028
(3 years from now)
| Active |
| US8173663 | Dipeptidyl peptidase inhibitors |
15 Mar, 2025
(3 months from now)
| Active |
| US8288539 | Dipeptidyl peptidase inhibitors |
15 Mar, 2025
(3 months from now)
| Active |
| US6890898 | Method of regulating glucose metabolism, and reagents related thereto |
02 Feb, 2019
(5 years ago)
| Expired |
| US7078381 | Method of regulating glucose metabolism, and reagents related thereto |
02 Feb, 2019
(5 years ago)
| Expired |
| US7459428 | Method of regulating glucose metabolism, and reagents related thereto |
02 Feb, 2019
(5 years ago)
| Expired |
| US6303661 | Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals |
24 Apr, 2017
(7 years ago)
| Expired |
| US6303640 | Pharmaceutical composition |
09 Aug, 2016
(8 years ago)
| Expired |
| US5965584 | Pharmaceutical composition |
19 Jun, 2016
(8 years ago)
| Expired |
| US6150383 | Pharmaceutical composition |
19 Jun, 2016
(8 years ago)
| Expired |
| US6150384 | Pharmaceutical composition |
19 Jun, 2016
(8 years ago)
| Expired |
| US6166042 | Pharmaceutical composition |
19 Jun, 2016
(8 years ago)
| Expired |
| US6166043 | Pharmaceutical composition |
19 Jun, 2016
(8 years ago)
| Expired |
| US6172090 | Pharmaceutical composition |
19 Jun, 2016
(8 years ago)
| Expired |
| US6211205 | Pharmaceutical composition |
19 Jun, 2016
(8 years ago)
| Expired |
| US6271243 | Pharmaceutical composition |
19 Jun, 2016
(8 years ago)
| Expired |
| US6329404 | Pharmaceutical composition |
19 Jun, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Oseni's drug page
33. Prevacid
Prevacid is protected by 12 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6328994
(Pediatric)
| Orally disintegrable tablets |
17 Nov, 2019
(5 years ago)
| Expired |
| US7431942
(Pediatric)
| Orally disintegrable tablets |
17 Nov, 2019
(5 years ago)
| Expired |
| US7875292
(Pediatric)
| Orally disintegrable tablets |
17 Nov, 2019
(5 years ago)
| Expired |
| US9901546
(Pediatric)
| Orally disintegrable tablets |
17 Nov, 2019
(5 years ago)
| Expired |
| US6328994 | Orally disintegrable tablets |
17 May, 2019
(5 years ago)
| Expired |
| US7431942 | Orally disintegrable tablets |
17 May, 2019
(5 years ago)
| Expired |
| US7875292 | Orally disintegrable tablets |
17 May, 2019
(5 years ago)
| Expired |
| US9901546 | Orally disintegrable tablets |
17 May, 2019
(5 years ago)
| Expired |
| US7399485
(Pediatric)
| Rapidly Disintegrable solid preparation |
26 Nov, 2018
(5 years ago)
| Expired |
| US7399485 | Rapidly Disintegrable solid preparation |
26 May, 2018
(6 years ago)
| Expired |
| US5464632
(Pediatric)
| Rapidly disintegratable multiparticular tablet |
07 May, 2013
(11 years ago)
| Expired |
| US5464632 | Rapidly disintegratable multiparticular tablet |
07 Nov, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Prevacid's drug page
34. Rozerem
Rozerem is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10098866 | Pharmaceutical preparation containing copolyvidone |
16 Nov, 2021
(3 years ago)
| Expired |
| US6034239 | Tricyclic compounds, their production and use |
22 Jul, 2019
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rozerem's drug page
35. Trintellix
Trintellix is protected by 21 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9278096
(Pediatric)
| Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity |
21 Sep, 2032
(7 years from now)
| Active |
| US9278096 | Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity |
21 Mar, 2032
(7 years from now)
| Active |
| US8722684
(Pediatric)
| 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
30 Dec, 2031
(7 years from now)
| Active |
| US8722684 | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
30 Jun, 2031
(6 years from now)
| Active |
| US11458134
(Pediatric)
| 1-[2-(2,4-dimeihylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
15 Dec, 2027
(3 years from now)
| Active |
| US8969355
(Pediatric)
| 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment |
15 Dec, 2027
(3 years from now)
| Active |
| US9125908
(Pediatric)
| 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
15 Dec, 2027
(3 years from now)
| Active |
| US9125909
(Pediatric)
| 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
15 Dec, 2027
(3 years from now)
| Active |
| US9125910
(Pediatric)
| 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
15 Dec, 2027
(3 years from now)
| Active |
| US9227946
(Pediatric)
| 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment |
15 Dec, 2027
(3 years from now)
| Active |
| US9861630
(Pediatric)
| 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
15 Dec, 2027
(3 years from now)
| Active |
| US11458134 | 1-[2-(2,4-dimeihylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
15 Jun, 2027
(2 years from now)
| Active |
| US8969355 | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment |
15 Jun, 2027
(2 years from now)
| Active |
| US9125908 | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
15 Jun, 2027
(2 years from now)
| Active |
| US9125909 | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
15 Jun, 2027
(2 years from now)
| Active |
| US9125910 | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
15 Jun, 2027
(2 years from now)
| Active |
| US9227946 | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment |
15 Jun, 2027
(2 years from now)
| Active |
| US9861630 | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
15 Jun, 2027
(2 years from now)
| Active |
| US7144884
(Pediatric)
| Phenyl-piperazine derivatives as serotonin reuptake inhibitors |
17 Dec, 2026
(2 years from now)
| Active |
| US7144884 | Phenyl-piperazine derivatives as serotonin reuptake inhibitors |
17 Jun, 2026
(1 year, 6 months from now)
| Active |
| US8476279 | Phenyl-piperazine derivatives as serotonin reuptake inhibitors |
02 Oct, 2022
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Trintellix's drug page
36. Uloric
Uloric is protected by 5 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8372872 | Methods for concomitant treatment of theophylline and febuxostat |
08 Sep, 2031
(6 years from now)
| Active |
| US9107912 | Methods for concomitant treatment of theophylline and febuxostat |
08 Sep, 2031
(6 years from now)
| Active |
| US7361676 | Solid preparation containing single crystal form |
08 Mar, 2024
(8 months ago)
| Expired |
| US6225474 | Polymorphs of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and method of producing the same |
18 Jun, 2019
(5 years ago)
| Expired |
| US5614520 | 2-arylthiazole derivatives and pharmaceutical composition thereof |
25 Mar, 2019
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Uloric's drug page
37. Velcade
Velcade is protected by 11 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6713446
(Pediatric)
| Formulation of boronic acid compounds |
25 Jul, 2022
(2 years ago)
| Expired |
| US6958319
(Pediatric)
| Formulation of boronic acid compounds |
25 Jul, 2022
(2 years ago)
| Expired |
| US6713446 | Formulation of boronic acid compounds |
25 Jan, 2022
(2 years ago)
| Expired |
| US6958319 | Formulation of boronic acid compounds |
25 Jan, 2022
(2 years ago)
| Expired |
| US5780454
(Pediatric)
| Boronic ester and acid compounds |
03 Nov, 2017
(7 years ago)
| Expired |
| US5780454 | Boronic ester and acid compounds |
03 May, 2017
(7 years ago)
| Expired |
| US6083903 | Boronic ester and acid compounds, synthesis and uses |
28 Oct, 2014
(10 years ago)
| Expired |
| US6297217 | Boronic ester and acid compounds, synthesis and uses |
28 Oct, 2014
(10 years ago)
| Expired |
| US6617317 | Boronic ester and acid compositions |
28 Oct, 2014
(10 years ago)
| Expired |
| US6747150 | Boronic ester and acid compounds, synthesis and uses |
28 Oct, 2014
(10 years ago)
| Expired |
| US7119080 | Boronic ester and acid compounds, synthesis and uses |
28 Oct, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Velcade's drug page
38. Vyvanse
Vyvanse is protected by 44 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7105486
(Pediatric)
| Abuse-resistant amphetamine compounds |
24 Aug, 2023
(1 year, 2 months ago)
| Expired |
| US7223735
(Pediatric)
| Abuse resistant lysine amphetamine compounds |
24 Aug, 2023
(1 year, 2 months ago)
| Expired |
| US7655630
(Pediatric)
| Abuse-resistant amphetamine prodrugs |
24 Aug, 2023
(1 year, 2 months ago)
| Expired |
| US7659253
(Pediatric)
| Abuse-resistant amphetamine prodrugs |
24 Aug, 2023
(1 year, 2 months ago)
| Expired |
| US7659254
(Pediatric)
| Abuse-resistant amphetamine prodrugs |
24 Aug, 2023
(1 year, 2 months ago)
| Expired |
| US7662787
(Pediatric)
| Abuse resistant lysine amphetamine compounds |
24 Aug, 2023
(1 year, 2 months ago)
| Expired |
| US7662788
(Pediatric)
| Abuse-resistant amphetamine prodrugs |
24 Aug, 2023
(1 year, 2 months ago)
| Expired |
| US7671030
(Pediatric)
| Abuse-resistant amphetamine prodrugs |
24 Aug, 2023
(1 year, 2 months ago)
| Expired |
| US7671031
(Pediatric)
| Abuse-resistant amphetamine prodrugs |
24 Aug, 2023
(1 year, 2 months ago)
| Expired |
| US7674774
(Pediatric)
| Abuse-resistant amphetamine prodrugs |
24 Aug, 2023
(1 year, 2 months ago)
| Expired |
| US7678770
(Pediatric)
| Abuse-resistant amphetamine prodrugs |
24 Aug, 2023
(1 year, 2 months ago)
| Expired |
| US7678771
(Pediatric)
| Abuse-resistant amphetamine prodrugs |
24 Aug, 2023
(1 year, 2 months ago)
| Expired |
| US7687466
(Pediatric)
| Abuse-resistant amphetamine prodrugs |
24 Aug, 2023
(1 year, 2 months ago)
| Expired |
| US7687467
(Pediatric)
| Abuse-resistant amphetamine prodrugs |
24 Aug, 2023
(1 year, 2 months ago)
| Expired |
| US7700561
(Pediatric)
| Abuse-resistant amphetamine prodrugs |
24 Aug, 2023
(1 year, 2 months ago)
| Expired |
| US7713936
(Pediatric)
| Abuse-resistant amphetamine prodrugs |
24 Aug, 2023
(1 year, 2 months ago)
| Expired |
| US7718619
(Pediatric)
| Abuse-resistant amphetamine prodrugs |
24 Aug, 2023
(1 year, 2 months ago)
| Expired |
| US7723305
(Pediatric)
| Abuse-resistant amphetamine prodrugs |
24 Aug, 2023
(1 year, 2 months ago)
| Expired |
| US7105486 | Abuse-resistant amphetamine compounds |
29 Jun, 2023
(1 year, 4 months ago)
| Expired |
| US7223735 | Abuse resistant lysine amphetamine compounds |
29 Jun, 2023
(1 year, 4 months ago)
| Expired |
| US7700561 | Abuse-resistant amphetamine prodrugs |
29 Jun, 2023
(1 year, 4 months ago)
| Expired |
| US7687467 | Abuse-resistant amphetamine prodrugs |
08 Apr, 2023
(1 year, 7 months ago)
| Expired |
| US7678770 | Abuse-resistant amphetamine prodrugs |
25 Mar, 2023
(1 year, 7 months ago)
| Expired |
| US7678771 | Abuse-resistant amphetamine prodrugs |
25 Mar, 2023
(1 year, 7 months ago)
| Expired |
| US7674774 | Abuse-resistant amphetamine prodrugs |
18 Mar, 2023
(1 year, 7 months ago)
| Expired |
| US7671031 | Abuse-resistant amphetamine prodrugs |
28 Feb, 2023
(1 year, 8 months ago)
| Expired |
| US7105486 | Abuse-resistant amphetamine compounds |
24 Feb, 2023
(1 year, 8 months ago)
| Expired |
| US7223735 | Abuse resistant lysine amphetamine compounds |
24 Feb, 2023
(1 year, 8 months ago)
| Expired |
| US7655630 | Abuse-resistant amphetamine prodrugs |
24 Feb, 2023
(1 year, 8 months ago)
| Expired |
| US7659253 | Abuse-resistant amphetamine prodrugs |
24 Feb, 2023
(1 year, 8 months ago)
| Expired |
| US7659254 | Abuse-resistant amphetamine prodrugs |
24 Feb, 2023
(1 year, 8 months ago)
| Expired |
| US7662787 | Abuse resistant lysine amphetamine compounds |
24 Feb, 2023
(1 year, 8 months ago)
| Expired |
| US7662788 | Abuse-resistant amphetamine prodrugs |
24 Feb, 2023
(1 year, 8 months ago)
| Expired |
| US7671030 | Abuse-resistant amphetamine prodrugs |
24 Feb, 2023
(1 year, 8 months ago)
| Expired |
| US7671031 | Abuse-resistant amphetamine prodrugs |
24 Feb, 2023
(1 year, 8 months ago)
| Expired |
| US7674774 | Abuse-resistant amphetamine prodrugs |
24 Feb, 2023
(1 year, 8 months ago)
| Expired |
| US7678770 | Abuse-resistant amphetamine prodrugs |
24 Feb, 2023
(1 year, 8 months ago)
| Expired |
| US7678771 | Abuse-resistant amphetamine prodrugs |
24 Feb, 2023
(1 year, 8 months ago)
| Expired |
| US7687466 | Abuse-resistant amphetamine prodrugs |
24 Feb, 2023
(1 year, 8 months ago)
| Expired |
| US7687467 | Abuse-resistant amphetamine prodrugs |
24 Feb, 2023
(1 year, 8 months ago)
| Expired |
| US7700561 | Abuse-resistant amphetamine prodrugs |
24 Feb, 2023
(1 year, 8 months ago)
| Expired |
| US7713936 | Abuse-resistant amphetamine prodrugs |
24 Feb, 2023
(1 year, 8 months ago)
| Expired |
| US7718619 | Abuse-resistant amphetamine prodrugs |
24 Feb, 2023
(1 year, 8 months ago)
| Expired |
| US7723305 | Abuse-resistant amphetamine prodrugs |
24 Feb, 2023
(1 year, 8 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vyvanse's drug page